Cytosorbents (CTSO) Awarded $4.3M Contract by the U.S. DoD to Develop HemoDefend-BGA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 1/27/2023
- Wall Street closes green as GDP data eases recession worries
- Intel sinks after forecasting weaker than expected start to 2023
- Hasbro cuts 15% of workforce, warns for Q4 on weak consumer business
- Visa reports better than expected Q1 results
- Bulls win Tesla 'Super Bowl' on demand as bears focus on plunging gross margins
- Bed Bath & Beyond (BBBY) Names Carol Flaton to Board of Directors
- Genelux Corp (GNLX) Prices 2.5M Share IPO at $6/sh, Top of Range
- Oracle (ORCL) Health Cloud Leader Don Johnson Resigns - Business Insider
- ChatGPT Gives Tips on How to Invest in ChatGPT
- Wall Street closes green as GDP data eases recession worries
- After-hours movers: Intel sinks on humiliating guidance, Visa gains on earnings
- Midday movers: Tesla, Chevron, Southwest Airlines and more
- After-hours movers: Tesla ticks up on beat, Chevron jumps on massive buyback
- Midday movers: Microsoft, Tesla, Boeing and more
- Microsoft, Boeing fall premarket; Fox, News Corp and AT&T rise
CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma
October 6, 2022 7:00 AM EDTPRINCETON, N.J., Oct. 6, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the Company a three-year Phase III contract valued at $4,292,641 to customize the design of the HemoDefend-BGA filter for sterile integration into collections systems for freeze-dried plasma processing to generate freeze-dried universal plasma. Without the need for blood typing,... More
